Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Rises By 19.0%

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) saw a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 52,600 shares, a growth of 19.0% from the October 31st total of 44,200 shares. Based on an average trading volume of 64,200 shares, the short-interest ratio is presently 0.8 days.

Entera Bio Stock Down 3.5 %

Shares of NASDAQ:ENTX traded down $0.06 during midday trading on Friday, reaching $1.64. The company's stock had a trading volume of 6,238 shares, compared to its average volume of 131,891. The firm has a market capitalization of $58.68 million, a PE ratio of -6.31 and a beta of 1.58. Entera Bio has a twelve month low of $0.52 and a twelve month high of $3.35. The stock has a fifty day moving average of $1.79 and a 200 day moving average of $1.86.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Entera Bio in a report on Monday, November 11th.

Institutional Trading of Entera Bio

A number of hedge funds and other institutional investors have recently made changes to their positions in ENTX. Virtu Financial LLC purchased a new position in Entera Bio during the first quarter worth about $37,000. Signature Estate & Investment Advisors LLC purchased a new position in Entera Bio during the third quarter worth about $90,000. Finally, Parkman Healthcare Partners LLC raised its stake in Entera Bio by 2.4% during the third quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company's stock worth $781,000 after purchasing an additional 9,558 shares during the period. Institutional investors and hedge funds own 14.11% of the company's stock.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.